Company Analysis ГЕНЕТИКО
1. Summary
Advantages
- Price (30.68 ₽) is less than fair price (56.91 ₽)
Disadvantages
- Dividends (0%) are below the sector average (9.06%).
- The stock's return over the last year (-37.13%) is lower than the sector average (-3.6%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=130.18%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| ГЕНЕТИКО | Потреб | Index | |
|---|---|---|---|
| 7 days | -0.9% | 3.1% | 2.2% |
| 90 days | -0.1% | 8.2% | 6.3% |
| 1 year | -37.1% | -3.6% | -7.6% |
GECO vs Sector: ГЕНЕТИКО has significantly underperformed the "Потреб" sector by -33.53% over the past year.
GECO vs Market: ГЕНЕТИКО has significantly underperformed the market by -29.48% over the past year.
Stable price: GECO is not significantly more volatile than the rest of the market on "Московская биржа" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GECO with weekly volatility of -0.7141% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (30.68 ₽) is lower than the fair price (56.91 ₽).
Price significantly below the fair price: The current price (30.68 ₽) is 85.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (10.89).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (14.68).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is lower than that of the sector as a whole (30.67).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (10.15).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (1.43).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (1.91).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (6.26).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (2.22).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (130.18%).
ROE vs Market: The company's ROE (0%) is lower than that of the market as a whole (68.42%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (11.14%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (17.61%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (14.31%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.32%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '9.06%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum ГЕНЕТИКО
9.2. Latest Blogs
💊 Слыхали про супер-лекарство от наших фарм-компаний?
- ❌ Нет ?
Да я тоже нет, но судя по темпам роста , - оно есть.
🦠 Что там за напасть в Китае (где ж ещё опять) ?
Метапневмовирус - является одним из возбудителей респираторных инфекций, был открыт аж в в 2001 году.
Чаще всего вызывает острые респираторные инфекции, включая бронхиолит, пневмонию....
More
🤔 Интересно наблюдать как изменились цены компаний после выхода на ipo
Вот плюсовые из них
#GECO #geco +68%
#ASTR #astr +7%
#SVCB #svcb +7%
#UGLD #ugld +15%
#DIAS #dias +3%
#POSI #posi +200%
данные на 06.11.24
Статье лайк 👍 если пост был для вас полезным
Подписывайтесь 🖖 будем и дальше анализировать потенциал компаний.
Есть интересные идеи 💡
More
Озон-фармацевтика. Анализ перед IPO
К сожалению, не было времени записать полноценный видео-разбор, хотя очень хотелось… Решил привести положительные и отрицательные стороны, которые нравятся/смущают. Так уже делал в рамках прошлых обзоров. Кто пришел лишь за buy или sell, скажу сразу, участвую, но на небольшую долю, без фанатизма, чтобы взять 1-2% от портфеля, а дальше - наблюдать....
More
All blogs ⇨
